TrialSignal transduction and targeted therapy2025

Multicenter phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors.

Pei Shu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.